Key Investor Signals
Built on biomarker research involving nearly 2,000 patients
CEO Mikael Benson’s academic team tested candidate prostate-cancer biomarkers in blood, tissue and urine from nearly 2,000 patients in research published in 2025.
Commercializing Karolinska digital-twin research
CancerTwin was created from the Swedish Digital Twin Consortium and Karolinska Institutet’s Medical Digital Twin Research Group, turning that research into a cancer-diagnostics venture.
Added Harvard physician-scientist Joseph Loscalzo as advisor
CancerTwin’s scientific advisor is Joseph Loscalzo, a Harvard Medical School professor whose work includes systems biology and network approaches to medicine.
Other Positive Signals
- Built on 2025 publications exploring how digital twins can support personalized medicine.
Team
Mikael Benson
CEO
- Leads Karolinska Institutet’s Medical Digital Twin Research Group, integrating clinical and molecular data for personalized medicine.
- Led the 2025 prostate-cancer study that tested candidate biomarkers across blood, tissue and urine from nearly 2,000 patients.
- Co-authored 2025 Nature Biotechnology and Genome Medicine papers on medical digital twins for preventive and personalized medicine.
Product
CancerTwin builds computational tumor models at the level of diagnostic groups, subtypes and individuals. The models combine clinical information with multi-omics measurements, including data describing individual cells and their position within tissue.
Combining clinical and molecular information
The modeling workflow integrates routine clinical variables with different layers of biological data. Spatial single-cell measurements help represent both the activity and location of cells within a tumor.
Modeling disease groups and individual tumors
Digital twins represent relevant biological interactions at different scales, from broad diagnostic groups to individual patients. Computational analysis prioritizes mechanisms associated with early disease.
Prioritizing markers for practical testing
The platform seeks measurable biomarkers and potential drug targets from model outputs. Candidate diagnostic signals then require laboratory and clinical evaluation before they can support routine patient decisions.
Market Overview
Earlier cancer diagnosis and individualized monitoring are major priorities for health systems and diagnostic developers. Biomarker discovery must balance biological detail with tests that are practical, reproducible and affordable. Broad cancer incidence describes the clinical need, while each validated test would serve a narrower indication and population.
The commercial opportunity sits within oncology diagnostics and biomarker discovery, where laboratories and test developers seek non-invasive signals that can detect disease earlier and stratify patients more precisely. Prostate cancer provides an initial proof area: improved biomarkers could reduce unnecessary biopsies while supporting earlier diagnosis.
An estimated 20 million new cancer cases occurred worldwide in 2022.
In 2022, an estimated 53.5 million people worldwide were alive within five years of a cancer diagnosis.
An estimated 1.5 million new prostate cancer cases occurred worldwide in 2022.
Only 39% of 115 countries surveyed by WHO covered basic cancer management in financed core health services for all citizens.
Comparable Outcomes
Decipher Biosciences
Developed genomic tests that assessed prostate cancer risk and helped clinicians guide treatment decisions. Veracyte completed its $600 million cash acquisition of Decipher Biosciences in March 2021.
Paige
Developed AI for digital pathology, using clinically annotated tissue images to support cancer diagnosis, biomarker discovery and research. Tempus acquired Paige in August 2025 for $81.25 million, expanding its AI-powered digital pathology capabilities.
Interested in More Startups Like CancerTwin?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.